Click here to see the latest financial report.
Review of Activities, Achievements and Future Plans 2024.
Our research work at St George’s, University of London has continued with the help of our new PhD student who has settled in well with the team. Within the first six months, a solid foundation for the direction of future research was established, the focus being on novel therapeutics which may attack pancreatic cancer cells. Initial results have shown exciting data and now it’s necessary to understand the mechanism by which these drugs work.
Donations have picked up from the period affected by covid but are still down on pre-covid days. Tight pressure on household budgets has seen a marked decrease in ad-hoc donations but with tight control of expenses, we feel able to continue this important research.
Our participation in an appeal for funds to support research at Oxford University continued into this financial year. The donations received are restricted to research being carried out by a specific team and were made in memory of Richard Nevill, who was undergoing private treatment for pancreatic cancer administered by this team. Unfortunately, he died during the appeal, but the research team (which is now based in the University of Birmingham) will continue their research funded by the donations made in Richard’s name. Final payments to the University of Birmingham were made by us in March 2024 and our involvement in the appeal has ended. There will, however, be research collaboration between our team at St George’s and the one at Birmingham as necessary.
On 1 August 2024, the business and assets of St George’s will transfer to City, University of London, under a merger Agreement between the two organisations. The merged businesses will be renamed “City St George’s, University of London”. The Trustees do not feel this merger will have any effect on our research.
FINANCIAL REVIEW
During the year donations and other income amounted to £90,516 (2023 – £70,435) and expenditure was £215,997 (2023 – £5,463) leaving an excess of Expenditure over Income of £125,480 (2023 – surplus of £64,972), which is transferred to the Unrestricted Funds brought forward which stand at minus £24,757 and Restricted £498, totalling minus £24,259 (2023- £101,221).
See previous financial reports:
